FDA Brief

Warning letters Drugs

FDA warning letter to

Dry Springs Pharmacy

High riskIssued Apr 1Posted Apr 14Center for Drug Evaluation and Research (CDER)

FDA warned Dry Springs Pharmacy that its website sells unapproved and misbranded opioids, benzodiazepines, and stimulants to U.S. consumers.

What happened

FDA reviewed www.dryspringspharmacy.net and found it offering prescription opioids, benzodiazepines, and Schedule II stimulants for sale to U.S. consumers without prescriptions. The letter says examples include OxyNorm/oxycodone, Yellow Xanax/alprazolam, and Adderall/amphetamine, and that no FDA-approved applications are in effect for these products. FDA says the website introduces unapproved and misbranded drugs into interstate commerce.

What FDA found

  1. The website offered unapproved new opioid drugs, including OxyNorm and oxycodone, without FDA-approved applications.

    FD&C Act § 505(a) [21 U.S.C. § 355(a)]; § 301(d) [21 U.S.C. § 331(d)]
  2. The website offered unapproved new benzodiazepine drugs, including Yellow Xanax and alprazolam, without FDA-approved applications.

    FD&C Act § 505(a) [21 U.S.C. § 355(a)]; § 301(d) [21 U.S.C. § 331(d)]
  3. The website offered an unapproved new Schedule II stimulant, Adderall/amphetamine, without an FDA-approved application.

    FD&C Act § 505(a) [21 U.S.C. § 355(a)]; § 301(d) [21 U.S.C. § 331(d)]
  4. The website offered prescription drugs without requiring a prescription, making them misbranded.

    FD&C Act § 503(b)(1) [21 U.S.C. § 353(b)(1)]; § 301(k) [21 U.S.C. § 331(k)]
  5. The labeling for the prescription drugs lacked adequate directions for use by a layperson.

    FD&C Act § 502(f)(1) [21 U.S.C. § 352(f)(1)]
  6. Offering these drugs for sale caused misbranded drugs to be introduced into interstate commerce.

    FD&C Act § 301(a) [21 U.S.C. § 331(a)]

What FDA wants

FDA asks the company to stop offering any unapproved and misbranded drugs to U.S. consumers. It also asks for a written response within 15 working days describing steps taken and how recurrence will be prevented, with documentation; if corrections cannot be completed in that time, state the reason and completion date.

Who should pay attention

  • U.S. consumers who buy prescription drugs online
  • online pharmacies that ship to U.S. customers
  • companies that advertise or link to overseas drug sellers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Phuoc Loc Tho Herbals, Inc.

    FDA warned Phuoc Loc Tho Herbals that its herbal products are unapproved new drugs marketed with disease claims.

    High risk
  4. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk